Your selection

Innovation / 11.05.2020
US health authorities to provide USD 6 million in funding for MYELO radiation protection pill

Berlin-based MYELO Therapeutics, an affiliated company of Eckert & Ziegler Strahlen- und Medizintechnik AG, will receive USD 6 million from the National Institutes of Health (NIH) over the next three years for the further development of its radiation protection pill MYELO001. The company is one of the few European applicants to successfully compete for funds from the relatively generous US catastrophe prevention program.

The money will be used to finance further tests and proof of concept and to investigate the functional mechanism of the new orally applicable drug. If the multi-year trials are successful, MYELO has the opportunity to win valuable contracts from civil protection agencies in America and elsewhere to build up emergency stocks.

"MYELO Therapeutics is one of a series of strategic investments that Eckert & Ziegler is using to push its growth into new dimensions in the mid term," explained Dr. Andreas Eckert, CEO of the TecDAX company Eckert & Ziegler. "The Executive Board has been able to continuously increase the financial resources for this purpose over the past few years. Although it would still be years too early to make concrete statements on sales or earnings potential, the award of the contract by the American health authorities shows that Eckert & Ziegler is on the right track when it comes to selecting its financing projects".

For details of the radiation protection pill and the funding commitment of the American health authorities, see the detailed press release of MYELO Therapeutics: http://www.myelotherapeutics.com/news.html

About Eckert & Ziegler.
Eckert & Ziegler Eckert & Ziegler Strahlen- und Medizintechnik AG with more 800 employees, is one of the world's largest providers of isotope-related components for radiation therapy and nuclear medicine. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.

Overview News

News Buch Berlin

Janggu makes deep learning a breeze

Researchers from the MDC have developed a new tool that makes it easier to maximize the power of deep learning for studying genomics. They describe the new approach, Janggu, in the journal Nature Comm...

more ...

B-cell protectors

A research group at the MDC has discovered a protein that protects mature B lymphocytes from stress-induced cell death. It also helps immune cells produce effective antibodies, which can stop the path...

more ...

Osmotic stress identified as stimulator of cellular waste disposal

Researchers from the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin have now discovered a previously unknown mechanism: osmotic stress, i.e. a change in water and ionic balanc...

more ...

Events Buch Berlin

05.08.2020, 09:00
Ein Ferientag zum Thema Bienen

13.08.2020, 09:00
GMP Biotech Summer School

Good Manufacturing Practice (GMP) Basic Course Biotechnology (English)

more ...

13.08.2020, 09:00
Realtime PCR und Digital PCR-Kurs

für erfahrene PCR Anwender*innen und an Einsteiger*innen

more ...

This website is supported by: